It has been famous in 1964, under the trade name Vanquish by Sterling Drug, which after a series of mergers and acquisitions became a unit of Bayer AG.In Germany, it is sold as dolomo, Dolopyrin AL, HA-Tabletten, Melabon K, Neuralgin, ratiopyrin, Thomapyrin Classic, Thomapyrin Intensiv, in Austria as Thomapyrin, and InfluASS, in Israel as Acamol Focus, Paramol Target and Exidol, in Romania as Antinevralgic P  and Antinevralgic Forte, and in Russia, Belarus and Eastern Europe as Citramon. == References ==
Luspatercept was approved for medical use in the European Union in June 2020.The U.S. Food and Drug Administration (FDA) awarded orphan drug status in 2013, and fast track designation in 2015. Research
Luspatercept is being evaluated for use in adults with non-transfusion dependent beta thalassemia. References
External links
"Luspatercept". Drug Information Portal. U.S. National Library of Medicine.